Tanya McNally
About Tanya McNally
Centene’s Chief People Officer (CPO) since March 2023, Tanya M. McNally (age 51) oversees human capital strategy and enterprise people programs; she served as Interim CPO (Jan–Mar 2023) after joining Centene via WellCare in 2018 and rising through HR leadership roles . During her CPO tenure, Centene delivered 2024 total revenues of $163B (+6% YoY), GAAP diluted EPS of $6.31 (+27% YoY), adjusted diluted EPS of $7.17 (+7% YoY), and a 3-year TSR CAGR of -10% as disclosed in the 2025 proxy; incentive plans tied payouts primarily to adjusted EPS and quality/enterprise goals . Her insider Form 3 (Feb 18, 2025) shows meaningful unvested RSUs and PSUs, indicating retention hooks through 2026–2027 and potential vesting-related trading windows in Mar/Apr 2025 and Jan 2026 .
Past Roles
| Organization | Role | Years | Strategic impact |
|---|---|---|---|
| Centene | Chief People Officer | Mar 2023–present | Leads enterprise human capital; plan sponsor/executive signatory for Amended & Restated Executive Severance and Change in Control Plan (administered by Compensation & Talent Committee) . |
| Centene | Interim Chief People Officer | Jan 2023–Mar 2023 | Transition leadership of People function . |
| Centene | Regional VP, Human Resources | May 2022–Dec 2022 | Regional HR leadership . |
| Centene | VP, Global HR Business Partner | Jan 2020–May 2022 | Enterprise HR business partnering . |
| WellCare Health Plans (acquired by Centene) | VP, Human Resources | Aug 2018–Jan 2020 | HR leadership prior to combination . |
External Roles
- No public company directorships or external board roles disclosed for McNally in Centene’s 2025 proxy or 2024/2025 10-K executive officer sections .
Fixed Compensation
Not disclosed in the 2025 Proxy’s Named Executive Officer (NEO) tables (McNally is not listed as a 2024 NEO). Base salary and bonus target figures for the CPO were not provided in proxy or 8-Ks reviewed .
Performance Compensation
Centene’s executive annual incentive and long-term incentive frameworks (applying to NEOs and generally to senior executives) emphasize pay-for-performance.
-
Annual Cash Incentive Plan design and 2024 outcomes (company-level):
- Metrics/weights: Adjusted diluted EPS (65%); Enterprise & Individual Goals (25%); Quality Goals (10%) .
- 2024 payout results: EPS achieved 167% of target (weighted 108.6%); Enterprise & Individual 130% (32.5%); Quality 169% (16.9%); Total payout 158% of target .
-
PSU design for current program:
- Metrics/weights for PSUs: Adjusted Pre-Tax Earnings Growth CAGR (34%); Average Adjusted Pre-tax Earnings Margin (33%); Relative TSR (33%) .
- Historical cycle example (2022–2024): Weighted payout 44.6% of target (driven by metric-level outcomes disclosed) .
2024 Annual Cash Incentive Plan Results
| Metric | Weight | Actual vs. Target | Weighted Payout % |
|---|---|---|---|
| Adjusted Diluted EPS | 65% | 167% | 108.6% |
| Enterprise & Individual Goals | 25% | 130% | 32.5% |
| Quality Goals | 10% | 169% | 16.9% |
| Total | 100% | — | 158% |
Long-Term Incentive Design (PSUs)
| PSU Metric | Weight | Notes |
|---|---|---|
| Adjusted Pre-Tax Earnings Growth CAGR | 34% | Company financial metric focus . |
| Average Adjusted Pre-tax Earnings Margin | 33% | Profitability quality metric . |
| Relative TSR | 33% | Market-relative alignment . |
Equity Ownership & Alignment
- Ownership policies and risk controls:
- Executives are subject to stock ownership guidelines (CEO 6x base salary; other NEOs 3x) and clawbacks; hedging and pledging are prohibited .
- Equity awards are double-trigger for change-in-control; no single-trigger employment agreements or stock grants .
Beneficial Ownership and Outstanding Awards (as of Feb 18, 2025)
| Item | Detail |
|---|---|
| Common stock beneficially owned (Form 3) | 28,745 shares D (direct) . |
| Included RSUs (unvested) | 14,037 RSUs within beneficial ownership . |
| Additional PSUs (unvested) | 9,765 PSUs outstanding (not included in 28,745), subject to 3-year performance conditions; grants on Mar 15, 2023 (2,073) and Mar 15, 2024 (7,692) . |
| Hedging/Pledging | Prohibited for executives . |
RSU Vesting Schedule Detail (from Form 3)
| Vest date(s) | Shares | Notes |
|---|---|---|
| Mar 15, 2025 | 809 | Single-tranche vest . |
| Mar 15, 2025; 2026; 2027 | 4,142 total | Vests in three equal annual installments starting Mar 15, 2025 . |
| Mar 15, 2025; 2026 | 2,566 total | Vests in two equal annual installments starting Mar 15, 2025 . |
| Apr 15, 2025; 2026 | 4,897 total | Vests in two equal annual installments starting Apr 15, 2025 . |
| Jan 15, 2026 | 1,623 | Single-tranche vest . |
Implication: Concentrated vesting windows in Mar/Apr 2025 and Jan/Apr 2026 create potential sell‑to‑cover activity typical for tax withholding; PSUs add performance-contingent retention through 2026–2027 .
Employment Terms
- Executive severance and change-in-control plan (company-wide framework; CPO executed company signatory):
- Administered by the Compensation & Talent Committee; plan sponsor/agent for service includes the Chief People Officer; plan updated/amended with company execution “By: /s/ Tanya McNally” .
- Double-trigger CoC: cash severance plus equity acceleration upon qualifying termination post-CoC; no excise tax gross-ups .
Executive Severance and Change-in-Control Plan Summary
| Scenario | Tier I (EVP/SVP) | Tier II (Market/BU CEO) | Tier III (Other) |
|---|---|---|---|
| Qualifying termination (not CoC) | 1x base salary + prorated target bonus; equity continued vesting 12 months; CLTIP prorated @ actual; 12 months COBRA; 6 months outplacement . | 1x base salary + prorated target bonus; equity continued vesting 12 months; CLTIP prorated @ actual; 12 months COBRA; 6 months outplacement . | 0.75x base salary + prorated target bonus; equity continued vesting 9 months; CLTIP prorated @ actual; 9 months COBRA; 6 months outplacement . |
| CoC qualifying termination (double‑trigger) | 2x base + 2x average bonus + prorated target bonus; full equity acceleration; CLTIP full vest; 18 months COBRA; 6 months outplacement . | 1.5x base + 1.5x average bonus + prorated target bonus; full equity acceleration; CLTIP full vest; 18 months COBRA; 6 months outplacement . | 1x base + 1x average bonus + prorated target bonus; full equity acceleration; CLTIP full vest; 12 months COBRA; 6 months outplacement . |
Note: McNally’s specific tier classification was not disclosed in filings reviewed; terms above reflect plan-level benefits by tier .
- Clawback policy: Company can recover performance-based cash and equity in specified circumstances .
Performance & Track Record (Company context during McNally’s tenure)
| Metric | 2024 | YoY/CAGR |
|---|---|---|
| Total Revenues ($B) | 163 | +6% YoY . |
| GAAP Diluted EPS | 6.31 | +27% YoY . |
| Adjusted Diluted EPS | 7.17 | +7% YoY; 3-year CAGR 12% (Adj EPS) . |
| 3-Year TSR CAGR | (10)% | As disclosed in proxy . |
- Operational achievements cited by management and Board:
- Improved Medicare Star Ratings; positioning Medicare business to breakeven in 2027 .
- Marketplace growth and fraud/waste/abuse integrity initiatives; #1 Marketplace carrier with ~4.4M members .
- Medicaid redetermination navigation with strong RFP renewals; largest US Medicaid MCO .
Compensation Structure Analysis
- Alignment mechanisms: Heavily weighted EPS and profitability in annual and long-term metrics; relative TSR in PSUs aligns to shareholder outcomes .
- Risk controls: No single-trigger equity; no hedging/pledging; clawbacks; independent consultant advises committee .
- 2024 incentive outcomes: Elevated annual payout (158% of target) vs negative 3-year TSR could draw investor scrutiny on metric mix/targets despite strong operational/financial execution .
Investment Implications
- Retention and selling pressure: Unvested RSUs and PSUs across 2025–2027 create retention incentives and near-term vesting events (Mar/Apr 2025; Jan/Apr 2026) that can produce routine sell‑to‑cover flows but do not imply discretionary selling; no pledging allowed reduces alignment risk .
- Change-in-control economics: Double-trigger severance with full equity acceleration under CoC termination protects management continuity while avoiding single-trigger windfalls; no excise tax gross-ups aligns with governance best practices .
- Pay-for-performance lens: Company-level metrics (EPS, quality, enterprise goals; profitability and TSR in PSUs) indicate an incentive framework geared to earnings quality and operational outcomes; 2024 payout levels reflect strong execution but investors may weigh this against TSR trajectory and macro policy volatility in managed care .
- Governance and ownership: Prohibitions on hedging/pledging and robust clawbacks plus stock ownership guidelines enhance alignment; McNally’s disclosed equity inventory suggests meaningful “skin in the game” across time horizons .
Sources
- Centene 2025 Definitive Proxy Statement (DEF 14A), filed Mar 27, 2025: executive officers, compensation programs, and corporate performance highlights .
- Centene 2024 Form 10-K (filed Feb 18, 2025): executive officers roster including McNally .
- Insider Form 3 (filed Feb 18, 2025) for Tanya M. McNally: beneficial ownership and detailed RSU/PSU vesting schedules .
- Executive Severance and Change-in-Control Plan summaries and execution (company signatory: Chief People Officer) .